Table 2 Characteristics of patients with and without AKI

Age mean (± standard deviation)

60 (± 8.6)

59.5 (8.6)

61.5 (8.7)

0.36

Male, n

29 (63%)

21 (66%)

8 (57%)

0.74

Cisplatin administrated, mean (± standard deviation)

166.2 (22.6)

168.8 (20.8)

160.9 (27.0)

0.3

Number of cycles, median [Q25-75]

2 [1–3]

2.5 [1–3]

1.5 [1–2.75]

0.27

Cisplatin cumulative dose, mean (± standard deviation)

386.5 (276.8)

406.8 (262.8)

340.3 (311.7)

0.46

History of alcohol (> 4U/day) and tobacco (≥ 10 pack-years) abuse, n

28 (61%)

20 (63%)

8 (57%)

0.75

No history of alcohol and tobacco abuse, n

7 (15%)

5 (16%)

2 (14%)

1

Cisplatin anteriority, n

7 (15%)

7 (22%)

0 (0%)

0.083

Diabetes, n

1 (2%)

1 (3%)

0 (0%)

1

Hypertension, n

15 (33%)

12 (38%)

3 (21%)

0.33

Ischemic heart disease, n

4 (9%)

3 (10%)

1 (3.1%)

0.078

Obliterative arteriopathy of the lower limbs, n

4 (9%)

2 (6.2%)

2 (14%)

0.57

Obstructive pulmonary disease, n

2 (4%)

1 (3.1%)

1 (7.1%)

0.52

Liver cirrhosis, n

3 (7%)

3 (9.4%)

0 (0%)

0.54

Male, n

29 (63%)

21 (66%)

8 (57%)

0.74

Meta yes, n

23 (50%)

14 (44%)

9 (64%)

0.34

Radiotherapy, n

40 (87%)

28 (88%)

12 (86%)

1

Initial tumor status, n

 N, n

0.47

  N0

6 (13%)

3 (9.4%)

3 (21%)

  N1

8 (17%)

6 (19%)

2 (14%)

  N2

23 (50%)

17 (53%)

6 (43%)

  N3

9 (20%)

6 (19%)

3 (21%)

  N4

0 (0%)

0 (0%)

0 (0%)

 T, n

0.32

  T1

1 (2%)

1 (2%)

0 (0%)

  T2

14 (30%)

11 (34%)

3 (21%)

  T3

13 (28%)

9 (28%)

4 (29%)

  T4

18 (39%)

10 (31%)

8 (57%)

Initial cancer location, n

0.49

 oropharynx

20 (44%)

15 (47%)

5 (36%)

 larynx

16 (35%)

10 (31%)

6 (43%)

 oral cavity

7 (15%)

3 (9%)

4 (29%)

 hypopharynx

2 (4%)

2 (6.2%)

0 (0%)

 nasopharynx

2 (4%)

2 (6.2%)

0 (0%)

 nasosinus

3 (7%)

3 (9%)

0 (0%)